- Trials with a EudraCT protocol (1,346)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (164)
1,346 result(s) found for: lymphoma.
Displaying page 43 of 68.
EudraCT Number: 2022-000891-20 | Sponsor Protocol Number: CA-4948-101 | Start Date*: 2023-02-03 | |||||||||||
Sponsor Name:Curis, Inc. | |||||||||||||
Full Title: An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or ... | |||||||||||||
Medical condition: Relapsed or Refractory Hematologic Malignancy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001673-14 | Sponsor Protocol Number: CCTL019A2205B | Start Date*: 2015-10-06 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy | ||||||||||||||||||
Medical condition: All patients who have been treated with chimeric antigen receptor (CAR) T-cell therapy in the context of a prior Novartis sponsored or supported study for any indication. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) GB (GB - no longer in EU/EEA) SE (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000620-17 | Sponsor Protocol Number: DRKS00005503 | Start Date*: 2014-04-28 |
Sponsor Name:Landeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart | ||
Full Title: High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma - randomized phase III trial | ||
Medical condition: Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) NO (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003689-28 | Sponsor Protocol Number: BrEPEM-LH-22017 | Start Date*: 2018-04-05 | |||||||||||
Sponsor Name:GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea) | |||||||||||||
Full Title: A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Ly... | |||||||||||||
Medical condition: Older Patients with Untreated Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-002414-19 | Sponsor Protocol Number: | Start Date*: 2008-05-22 | |||||||||||
Sponsor Name:GOELAMS | |||||||||||||
Full Title: Etude prospective multicentrique de phase II évaluant la radioimmunothérapie fractionnée avec un anticorps humanisé anti-CD22 marqué à l'yttrium 90 (90Y-DOTA-hLL2) en consolidation après immuno-chi... | |||||||||||||
Medical condition: lymphomes B agressifs disséminés du sujet de plus de 60 ans et de moins de 80 ans. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005496-10 | Sponsor Protocol Number: H6Q-MC-S028 | Start Date*: 2009-01-28 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: An Open-label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma | |||||||||||||
Medical condition: First-Line Diffuse Large B-Cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003949-14 | Sponsor Protocol Number: 26866138LYM2021 | Start Date*: 2008-08-18 | |||||||||||
Sponsor Name:ORTHO BIOTECH, Geschäftsbereich der JANSSEN-CILAG GmbH | |||||||||||||
Full Title: Pilot study of bortezomib under rituximab standard therapy in patients with relapsed or refractory follicular lymphoma and at least 2 prior therapies | |||||||||||||
Medical condition: Patients with histologically proven CD-20-positive follicular lymphoma grade I/II (WHO), stage III/IV (ANN ARBOR) relapsed or refractory to last treatment after at least 2 cytostatic therapies who ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002406-37 | Sponsor Protocol Number: 170 | Start Date*: 2016-02-24 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck Co., Inc | ||||||||||||||||||
Full Title: A Phase 2 Study of Pembrolizumab (MK 3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS) | ||||||||||||||||||
Medical condition: relapsed or refractory Primary Mediastinal Large B-Cell Lymphoma or Relapsed or Refractory Richter Syndrome (rrRS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) PL (Completed) ES (Completed) FR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-001628-72 | Sponsor Protocol Number: P001317 | Start Date*: 2017-07-18 |
Sponsor Name:Medical Center - University of Freiburg | ||
Full Title: Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients | ||
Medical condition: Primary central nervous system lymphoma (PCNSL) is an aggressive Non-Hodgkin Lymphoma (NHL) mostly of B-cell origin, which exclusively invades the central nervous system compartment. It accounts fo... | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000715-23 | Sponsor Protocol Number: FIL_COLUMN | Start Date*: 2021-12-14 | |||||||||||
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | |||||||||||||
Full Title: Consolidation with ADCT-402 (loncastuximab tesirine) after a short course of immunochemotherapy: a phase II study in BTKi-treated (or BTKi intolerant) Relapsed/Refractory (R/R) Mantle Cell Lymphoma... | |||||||||||||
Medical condition: Bruton Tyrosine Kinase inhibitors (BTKi) treated (or BTKi intolerant) relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003392-18 | Sponsor Protocol Number: FIL_RENOIR12 | Start Date*: 2014-04-17 |
Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS | ||
Full Title: A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituxim... | ||
Medical condition: Maintenance following R-chemotherapy (Rituximab-Bendamustine) of patients with follicular lymphoma in first or second relapse or progression and not eligible for autologous stem cell transplantatio... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005240-28 | Sponsor Protocol Number: PTCL-Dasa01 | Start Date*: 2014-06-10 | |||||||||||
Sponsor Name:AOU di Bologna, Policlinico S.Orsola-Malpighi | |||||||||||||
Full Title: OPEN LABEL, PHASE IIA MULTICENTER STUDY OF DASATINIB IN THE TREATMENT OF PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) RELAPSED/REFRACTORY OR NOT AMENABLE TO CONVENTIONAL THERAPY-PTCL-DASA01 | |||||||||||||
Medical condition: PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA (PTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001965-26 | Sponsor Protocol Number: AUTO4-TL1 | Start Date*: 2018-02-01 | |||||||||||
Sponsor Name:Autolus Ltd | |||||||||||||
Full Title: A SINGLE ARM, OPEN-LABEL, MULTI-CENTRE, PHASE I/II STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF AUTO4, A CAR T CELL TREATMENT TARGETING TRBC1, IN PATIENTS WITH RELAPSED OR REFRACTORY TRBC1 ... | |||||||||||||
Medical condition: Relapsed or refractory T cell Non-Hodgkin Lymphoma (T-NHL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005254-68 | Sponsor Protocol Number: GEL/TAMO-2006 | Start Date*: 2007-04-13 |
Sponsor Name:GEL/TAMO (Cooperative Spanish Group of Lymphoma/Autologous bone marrow transplant). | ||
Full Title: Treatment with R-MegaCHOP and early rescue with R-IFE and autologous stem cells transplant (ASCT) according response measured by positron emission tomography (PET) in patients with diffuse large B-... | ||
Medical condition: Diffuse Large B-Cell Lymphoma (DLBCL) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000222-51 | Sponsor Protocol Number: 06_DOG05_44 | Start Date*: 2007-09-07 |
Sponsor Name:Southampton University Hospitals NHS Trust | ||
Full Title: Short CHemo RadioImmunotherapy in Follicular Trial of 90Y Ibritumomab tiuxetan (ZevalinTM) as therapy for first and second relapse in Follicular Lymphoma | ||
Medical condition: Follicular Lymphoma First and second relapse of Follicular Lymphoma grade 1, 2, 3a. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-019832-11 | Sponsor Protocol Number: EMI114238 | Start Date*: 2010-07-13 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: An open-label study to evaluate the utility of the apoptosis imaging biomarker [18F]ML-10 to assess the response to chemotherapy in patients with non Hodgkin's lymphoma. | ||
Medical condition: Non Hodgkin’s lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2007-001589-34 | Sponsor Protocol Number: LNH03-7B | Start Date*: 2007-06-05 |
Sponsor Name:GELA Group | ||
Full Title: Phase II study of mini CHOP plus Rituximab in non previously treated patient aged over 80 years with CD20+ Diffuse Large B-cell Lymphoma | ||
Medical condition: CD20+ diffuse large B-cell lymphoma | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001094-16 | Sponsor Protocol Number: PROACT | Start Date*: 2017-08-08 | |||||||||||
Sponsor Name:South Tees NHS Foundation Trust | |||||||||||||
Full Title: Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity ... | |||||||||||||
Medical condition: Prevention of cardiotoxicity | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001959-37 | Sponsor Protocol Number: E7449-E044-101 | Start Date*: 2011-10-17 | |||||||||||||||||||||||||||||||
Sponsor Name:Eisai Limited | |||||||||||||||||||||||||||||||||
Full Title: An open label, multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects with Advanced Solid Tumours or with B-cell Malignancies and in Combinat... | |||||||||||||||||||||||||||||||||
Medical condition: Advanced solid tumors (including ovarian cancer, triple negative breast cancer, and advanced melanoma) and B-cell lymphomas | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-018866-21 | Sponsor Protocol Number: Protocollo FLR/R 2510 | Start Date*: 2010-07-19 | |||||||||||
Sponsor Name:A.I.L. (ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE, LINFOMI E MIELOMI | |||||||||||||
Full Title: Intensified program including Bendamustine followed by PBSC mobilization and high dose therapy and autograft for patients with relapsed or resistant CD 20+ Follicular Non Hodgkin Lymphoma: a multi... | |||||||||||||
Medical condition: RESISTANT FOLLICULAR NON HODGKIN LYNPHOMA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
